glp 1 white house Some Medicare recipients could soon be paying lower prices for GLP-1 medications. , During a press briefing Tuesday, Dr. Mehmet Oz confirmed a deal President Trump made with the Questions swirl after Trump's GLP-1

Endothelial cell dysfunction and the pathobiology of atherosclerosis

This study showed that the risk of recurrent pancreatitis in a cohort of patients taking GLP-1 receptor agonists (10%) was likely no greater than what is observed in the general population and that more than half of the episodes of recurrent pancreatitis were attributable to causes other than GLP-1 receptor agonist therapy

(Photo by Shalina Chatlani/Stateline) Massachusetts and Rhode Island are considering dropping GLP-1 drugs for obesity treatment from their Medicaid programs, continuing a trend of states that have stopped coverage of these expensive medications

The black market flood of counterfeit products, incorrectly dosed medications, and contaminated compounds poses genuine danger

Identification of glutathione-overproducing mutants via acrolein resistance A genetically diverse S